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Isoform speciﬁcityAkt (also known as PKB) is a survival kinase frequently up-regulated in cancer; three isoforms of Akt exist, and
among them Akt1 and Akt2 are the most widely and highly expressed. They share the same structure and acti-
vation mechanism and have many overlapping functions; nevertheless isoform-speciﬁc roles and substrates
have been reported, which are expected to rely on sequence diversities. In particular, a special role in differenti-
ating Akt1 andAkt2 isoforms has been assigned to the linker region, a short segment between the PH and the cat-
alytic domains. We have previously found that a residue in the linker region (Ser129) is directly phosphorylated
by protein kinase CK2 in Akt1; the phosphorylation of the homologous residue in Akt2 (Ser131) has never been
analyzed. Herewe show that Akt2, endogenously or ectopically expressed in different cell lines, is not phosphor-
ylated on Ser131 by CK2, while in vitro recombinant Akt2 is a CK2 substrate. These data support the hypothesis
that in vivo a steric hindrance occurs which prevents the access to the CK2 site. Additionally, we have found that
Ser129 phosphorylation is involved in the recognition of the Akt1-speciﬁc substrate palladin; this observation
provides an explanation of why Akt2, lacking Ser131 phosphorylation in the linker region, has a low efﬁciency
in targeting palladin. CK2-dependent phosphorylation is therefore a crucial eventwhich, discriminating between
Akt1 and Akt2, can account for different substrate speciﬁcities, and,more in general, for ﬁne tuning of Akt activity
in the control of isoform-dependent processes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Akt (also known as PKB) is an anti-apoptotic and pro-survival pro-
tein kinase, whose activity is frequently abnormally high in tumors
[1–5]. Three isoforms of this kinase exist, Akt1 (or PKBα), Akt2
(or PKBβ) and Akt3 (or PKBγ), with a different tissue distribution [6],
quite speciﬁc for Akt3, which is also usually expressed at lower levels
[7], and more ubiquitous for Akt 1 and 2. The three isoforms share a
very high sequence homology, and the same domain structure,
consisting of anN-terminal PH (pleckstrin homology) domain, followed
by a linker segment, the catalytic domain, and a short C-terminal hydro-
phobic motif. They also share the same activationmechanism, based onDTT, dithiothreitol; e.v., empty
ipitation; LC, liquid chromatog-
trometry; PBS, phosphate buffer
inase-1; PEI, polyethylenimine;
EN, phosphatase and tensin ho-
t., wild type
niversity of Padova, Via U. Bassi
39 0498276363.
.the phosphorylation of two major sites, Thr308 in the catalytic domain
(catalyzed by PDK1) and Ser473 at the hydrophobic C-terminus
(catalyzed by mTORC2 or DNA-dependent protein kinase [8,9]).
Although the roles of the three isoforms are considered to be largely
overlapping, the different phenotypes of Akt1, Akt2 and Akt3 knockout
mice have indicated that they can also act distinctly [10–12]. Indeed,
several isoform-speciﬁc functions have been reported [13,14], and in
particular an opposite effect on cell migration has been reported for
Akt1 and Akt2 by several laboratories: Toker and coworkers found
that, unexpectedly, Akt1 exerts an anti-migration and anti-invasion
role in some cancer cells [15]; other papers conﬁrmed and extended
this study [16,17], providing also interesting observations on the alter-
native role of Akt2, which, on the contrary, has a positive effect on cell
motility [3,18,19].
The reason for opposite roles of two isoforms so similar in structure
and, for other aspects, also in functions, is only partially understood:
several isoform-speciﬁc substrates have been identiﬁed (as reviewed
in [20]) and, in particular, the Akt1-speciﬁc substrate palladin was
found related to the effects of Akt1 on breast cancer cell migration
[21]. However, a molecular explanation for the substrate selectivity of
the different isoforms has never been provided. It is obviously expected
to reside on sequence diversities that dictate different biological
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substrates and protein partners.
There are three main regions with substantial sequence diversity
between the isoforms, which may be involved in regulating unique
functions: amino acids 43–50 (numbering for Akt1), amino acids 111–
145, and amino acids 453–465 [7]. Interestingly, a special role in differ-
entiating Akt involvement in cell migration has been assigned to the
linker region, a short sequence (108–153) between the PH and the cat-
alytic domains, that has been found to be responsible for the phosphor-
ylation of palladin by Akt1 [21].
Akt signaling is deeply intersected by protein kinase CK2. CK2 is a
ubiquitous and pleiotropic Ser/Thr kinase involved in different process-
es, with a special role in promoting cell survival and counteracting apo-
ptosis. Similar to Akt, also CK2 is abnormally highly expressed in
tumors, thus it is considered a promising therapeutic target [22–26],
and a CK2 inhibitor is already under clinical trials [27]. CK2 exerts its
anti-apoptotic function by means of many mechanisms, frequently im-
plying a “lateral action” of CK2, whose constitutive activity cooperates
with other survival pathways which depends on external signals [28].
The potentiation of Akt signaling occurs at different levels: CK2 acts up-
stream, by inhibiting the PTEN phosphatase (which prevents Akt activa-
tion) [29], and also directly on Akt, by physical association [30] and by
phosphorylation of Akt itself, as we have previously demonstrated
[31]. We found that CK2 phosphorylates Akt1 at Ser129, which is
located just in the linker region; this phosphorylation results in an Akt
hyper-activation (over the level induced by phosphoThr308 and
phosphoSer473) [31], and also contributes to maintain a higher phos-
phorylation of Thr308 [32]. All our previous work was directed to
Akt1, thus the question arises whether CK2 might phosphorylate also
Akt2 or not, with possible relevance to the unique functions of each
Akt isoform.
In this work we demonstrate that, despite the conservation of a CK2
consensus site in the Akt2 sequence corresponding to Akt1 Ser129, Akt2
is not phosphorylated by CK2 in cells, providing a possible explanation
of the molecular mechanism underlying isoform-speciﬁc functions.
2. Materials and methods
2.1. Antibodies
Total Akt1/2/3 antibody was from Santa Cruz Biotechnology, Akt1,
Akt2, phospho-Akt (T308), phospho-Akt (S473), Akt P-motif, total
GSK3, phospho-GSK3 (S9), total AS160, phospho-AS160 (T642) and
phospho-PRAS40 (T246) antibodies were from Cell Signaling Technolo-
gy. HA, His-tag, α-tubulin and β-actin antibodies were from Sigma;
anti-palladin was from Proteintech, anti-survivin from Epitomics.
Anti-CK2α, anti-phospho-Akt (S129) and its not-phosphorylated coun-
terpart were raised and puriﬁed as elsewhere described [31]. Secondary
antibodies towards rabbit and mouse IgG, conjugated to horse radish
peroxidase, were from PerkinElmer.
2.2. Plasmids
The expression vectors for the human HA-tagged Akt1 (pcDNA3.1-
HA-Akt1) and HA-tagged Akt2 (pcDNA3.1-HA-Akt2) were kindly sup-
plied by Prof. Sandra Marmiroli (Modena, Italy). HA-Akt1 Ser129Ala
mutant plasmid was produced as previously described [31]; HA-Akt2
Ser131Asp, HA-Akt2 Cys124Ala and HA-Akt2 Ser131Ala mutant plas-
mids were obtained with the ‘QuickChange-Site Directed Mutagenesis’
Kit (Stratagene) using pcDNA3.1-HA-Akt2 as template and two pairs
of synthetic oligonucleotide primers each complementary to opposite
strands of template: 5′-GGCTCCCCCAGTGACTCCGACACGACTGAGGA
GATGGAAG-3′ and 5′-CTTCCATCTCCTCAGTCGTGTCGGAGTCACTGGG
GGAGCC-3′ (for Akt2 Ser131Asp); 5′-GGACCCCATGGACTACAAGGCG
GGCTCCCCCAGTGACTCC-3′ and 5′-GGAGTCACTGGGGGAGCCCGCCTT
GTAGTCCATGGGGTCC-3′ (for Akt2 Cys124Ala); 5′-GGCTCCCCCAGTGACTCCGCCACGACTGAGGAGATGGAAG-3′ and 5′CTTCCATCTCCTCAGTCG
TGGCGGAGTCACTGGGGGAGCC-3′ (for Akt2 Ser131Ala). The mutation
was conﬁrmed by sequencing analysis.
2.3. Proteins
Recombinant active His-tagged Akt1 and Akt2 were purchased from
ActiveMotif. Recombinant CK2αwas expressed, puriﬁed [33] and kind-
ly donated by Dr. Stefania Sarno (Padova, Italy). λ-Phosphatase was
kindly donated by Dr. Marco Mazzorana (Didcot, Oxfordshire UK).
2.4. Cell culture
HEK 293T, HeLa, U2OS, C2C12, A375, HT1080 and 3T3-L1 cell lines
were maintained in Dulbecco's modiﬁed Eagle's medium (DMEM;
Sigma), supplementedwith 10% Fetal Bovine Serum, 2mM L-glutamine,
100U/ml penicillin and 100 mg/ml streptomycin (all from Sigma), in an
atmosphere containing 5% CO2. 3T3-L1 preadipocytes were grown to
conﬂuence, then adipogenic differentiationwas induced by the addition
of 1 μM dexamethasone, 0.5 mM 3-isobutyl-1-methyl-xantine (IBMX,
Sigma), and 2 μM insulin (Sigma), for 72 h [34].
2.5. Cell transfection and siRNA experiments
For ectopical Akt expression, cells were plated into 6-well plates
(2.5 × 105 cells/well) the day before transfection and grown to
about 70% conﬂuence. HEK 293T cells were transiently transfected
with 1–3 μg of plasmids by a standard calcium-phosphate procedure.
The transfectionmixturewas removed after 16 h, and cells were collect-
ed 30 h after transfection. HeLa and U2OS cells were transiently
transfected with 2–3 μg of plasmids using polyethylenimine (PEI;
Polysciences Inc.) according to the manufacturer's protocol; transfec-
tions were allowed to proceed for 30 h until cells were harvested.
C2C12 cells were transiently transfected with 1.5–3 μg of plasmids
using Lipofectamine 3000 Reagent (Invitrogen, Life technologies) ac-
cording to the manufacturer's protocol and cells were collected 48 h
after transfection.
For RNA interference experiments, C2C12 cells were plated into
6-well plates (1 × 105 cells/well) the day before transfection and
grown to about 50% conﬂuence. Cells were transfected with 50 nM
Akt1 or Akt2 speciﬁc siGENOME SMARTpool siRNAs (Dharmacon)
or aspeciﬁc siRNA siCONTROL RISCfree #1 (Dharmacon) as control,
using the transfecting reagent INTERFERin (Polyplus-transfection),
according to the manufacturer's recommendations. Transfections
were allowed to proceed for 72 h until cells were harvested.
2.6. Cell lysis and western blot analysis
Cell lysis was performed as described in [31]. Protein concentration
was determined by the Bradford method. Equal amounts of proteins
(5–50 μg) were loaded on 11% SDS/PAGE, blotted on Immobilon-P
membranes (Millipore), processed by western blot with the indicated
antibody, and detected by chemiluminescence on a Kodak Image Sta-
tion 440MM PRO. Quantitation of the signal was obtained by analysis
with the Kodak 1D Image software.
2.7. Immunoprecipitation experiments
Akt immunoprecipitations were performed with 50–80 μg of total
lysate proteins fromHA-tagged Akt transfected cells. Lysates were incu-
bated overnight at 4 °C with 2 μl of anti-HA antibody followed by 25 μl
protein A-Sepharose (Sigma-Aldrich) for 40min.Where indicated, prior
immunoprecipitation lysates were incubated with λ-phosphatase (6 μg)
at 30 °C for 1 h in the presence of 50mMHEPES pH 7.5, 500mMNaCl, 5%
glycerol, 10 mM DTT and 50 μMMnCl2.
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lysate proteins fromHeLa cells transfected with Akt isoforms as indicat-
ed and treated for 2 h with insulin (100 nM, Sigma), and okadaic acid
(0.2 μM, Alexis) for 1 h before collecting cells. Lysates were incubated
at 4 °C with 1.3 μg of anti-palladin antibody for 2 h followed by 100 μl
protein A-Sepharose (Sigma) for 40 min.
Immuno-complexes were washed twice with Tris–HCl 50 mM
(pH 7.5) and once with Tris 5 mM (pH 7.5) and directly analyzed by
SDS/PAGE and western blot, or used as CK2 substrate in in vitro phos-
phorylation assays (see below).
2.8. In vitro phosphorylation of Akt by CK2α
HA-Akt immunoprecipitated from overexpressing cells or puriﬁed
recombinant His-tag Akt1 and Akt2 (0.05–0.5 μg) were incubated for
20 min at 30 °C with 0.1 μg of recombinant CK2α in the presence of a
phosphorylation reaction mixture consisting of 50 mM Tris–HCl,
pH 7.5, 10 mMMgCl2, 10 μM [γ-33P]ATP (~5000 cpm/pmol), in a total
volume of 20 μl [35]. Reactionswere stopped by the addition of Laemmli
loading buffer. Samples were boiled for 5 min, run on 11% SDS/PAGE
and blotted on Immobilon-P membranes (Millipore); radioactive
bands were detected and quantiﬁed by autoradiography (Cyclone plus
storage phosphor system, PerkinElmer).
2.9. Mass spectrometry experiments
For themass spectrometry analysis of the phosphorylation sites, HA-
Akt1 and HA-Akt2 were immunoprecipitated from 500 μg proteins of
total lysates fromoverexpressingHEK 293T cellswith 8 μl of anti-HAan-
tibody. Precipitates were resolved by SDS-PAGE, gel bands correspond-
ing to Akt proteins were excised and in-gel digested with sequence
grade trypsin (Promega).
2.9.1. Phosphorylation site analysis
Dried tryptic peptides were dissolved in 0.2 M acetic acid/30% (v/v)
ACN and the digests were passed over a TiO2 column and eluted with
triﬂuoroacetic acid as elsewhere described [36]. Samples were analyzed
with an LTQ-Orbitrap instrument (ThermoFisher), coupled to a HPLC
split-less Eksigent 2D NanoLC system (Eksigent Technologies). The
HPLC autosampler injected 5 μl of peptide sample, which was trapped
on the precolumn Zorbax 300SB-C18 (Agilent Technologies) and
washed with 0.1% (v/v) formic acid. Peptides were separated on a re-
verse phase analytical column Zorbax 300SB-C18, at a ﬂow rate of
400 nl/min. A gradient was run from 5% to 40% ACN over 55 min, held
for 5 min, and then raised to 80% (over 0.1 min). The latter concentra-
tion was kept for 15 min before returning to 5% and re-equilibrating.
Mass spectra of all samples were always acquired in the positive ioniza-
tionmode, with anm/z scan range of 400–2000 Th. After the threemost
intense precursormasses inMSmodewere selected, their MS/MS scans
(with anm/z range of 50–2000 Th)were performedwith a dynamic ex-
clusion range of 240 s after the second peptide count. The collision-
induced dissociation (CID) and the higher-energy collisional dissocia-
tion (HCD) energies were set at 35 and 45 eV, respectively.
2.9.2. Database analysis
All LC–MS/MS data were processed using the Proteios2 Software En-
vironment (version 2.10.0, available at http://proteios2.immunoprot.
lth.se:8443/proteios/) and analyzed with Mascot. The enzyme was set
to trypsin with two allowed miss-cleavages, the instrument to ion
trap and peptide and fragmentmass tolerances of 5 ppm and 0.5 Da, re-
spectively with 0.01 as the false discovery rate. Searches were done
against UniProt version (2012-03) including a decoy data set.
Carbamidomethyl-Cys was set as a ﬁxed modiﬁcation and oxidation of
Met and phosphorylation of Ser/Thr and Tyr as variable modiﬁcations.
Positive identiﬁcations were accepted based on conﬁdence scores of at
least 95%with a false discovery rate of 0.01 (at both protein and peptidelevels). The MS/MS spectra of the peptides identiﬁed by Mascot were
veriﬁed manually.
2.10. Immunoﬂuorescence microscopy
HeLa cells, transfected as described above and seeded on glass cover-
slips (about 104 cells) were ﬁxed with 4% (v/v) paraformaldehyde
(Sigma) for 20 min and permeabilized with 0.1% (v/v) Triton X-100 in
PBS for 10min at 4 °C. Glass cover-slipswere incubated 2 hwith the pri-
mary antibodies anti-HA (1:100) and anti-CK2α (1:50) and 1 h at 37 °C
with secondary antibodies FITC anti-mouse (1:50; Dako Denmark) and
633 goat anti-rabbit (1:400, Alexa Fluor). Cells were counterstained
with Hoechst 33342 (1:10,000; Sigma). Cover glass slips weremounted
with ﬂuoromount solution (Sigma), and immunoﬂuorescence images
were captured with LEICA-TCS SP5 confocal microscopy (Wetzlar,
Germany) by using HCX PL APO lambda blue 63 × 1.4 oil immersion ob-
jective. Images were processed by LAS-AF software.
3. Results
In our previouswork we demonstrated that Akt1 transfected in HEK
293T cells was phosphorylated at Ser129 by protein kinase CK2 [31].
The sequence of Akt2 aligned to that of Akt1 around Ser129 shows
that the consensus for CK2 [37] is present also in Akt2 (Fig. 1A). There-
forewe decided to ectopically express Akt2 in cells, in order to check the
phosphorylation state of the homologous residue, Ser131 in Akt2. To
this purpose, we chose a number of cell lines because they were easy
and convenient to be transfected, but also C2C12 muscle cells where
Akt2 has been shown to have physiological functions (e.g. [38]), and
performed Akt1 and Akt2 transfection, followed by western blot analy-
sis of cell lysates with the phospho-speciﬁc Ser129 antibody. As shown
in Fig. 1B, no signalwasdetected in cellswhere Akt2was overexpressed,
while Akt1, expressed at a similar (or even lower) level, gave instead a
strong phospho-Ser129 signal; as expected, the Akt1mutant Ser129Ala,
used as negative control, was not reactive as well. The absence of anti-
phospoSer129 reactivity was common to all the cell lines used for
Akt2 expression (Fig. 1B), and in conditions where the canonical sites,
Ser473 and Thr308 (Akt1 numbering) were phosphorylated also in
Akt2 (Fig. 1C). Interestingly, an antibody raised against the same region
of Akt1, but devoid of phosphate on Ser129, reacts quite well with Akt2
(Fig. 1C), strongly suggesting that the absence of signal with anti-
phospoSer129 is not due to local substitutions in the Akt2 sequence. In-
cidentally, it is worth to note that the mechanism by which in Akt1
phosphoSer129 contributes to maintain a high level of phosphoThr308
(involving the chaperone protein Hsp90 and the phosphatase PP2A
[32]), seems not applicable to Akt2. In fact, as judged from theWB reac-
tivity, the Thr phosphorylation in Akt2 is particularly high despite the
absence of Ser131 phosphorylation.
Ser131 Akt2 phosphorylation was undetectable irrespective to the
cellular stimulation conditions, as demonstrated by the data obtained
in insulin-treated cells (Fig. 1D). Not even cell treatment with okadaic
acid, a potent inhibitor of protein phosphatases frequently used to
force Ser/Thr endogenous phosphorylation (e.g. [39]), was able to in-
duce any signal on Akt2 Ser131 (Fig. 1E).
We thenwanted to analyze the Ser131 phosphorylation level on en-
dogenous Akt2. For this purpose, different strategies were exploited.
First, we compared different cell lines for their expression of Akt1 and
Akt2, and their reactivity to anti-phosphoSer129 antibody. It was evi-
dent (Fig. 2A) that this latter does not correlate at all with the level of
Akt2 expression (which is higher in adipocytes), while it displays a pat-
tern very similar to Akt1 expression, consistent with the view that Akt2
does not contribute to the total phosphorylation level of this site. Then
we focused on C2C12 cell line, andwe performed individual Akt isoform
silencing by RNA interference technology; as shown in Fig. 2B,we found
that Akt1 knock-down completely abolishes Ser129 phosphorylation,
while Akt2 knock-down has no effect on phosphoSer129. Conversely,
Fig. 1. Lack of reactivity of overexpressed Akt2 with anti-phospho-Ser129. A. Alignment of human Akt1 and Akt2 sequences around the CK2 site in Akt1 (Ser129) and the minimum CK2
consensus site are shown. B. 10 μg of proteins from total lysates of different transfected cell lineswas analyzed byWBwith the indicated antibodies. C. HEK 293T cellswere transfectedwith
HA-Akt1 or HA-Akt2; 10 μg of proteins was analyzed byWBwith the indicated antibodies. D. HeLa or C2C12 cells, transfected as indicated, were left untreated or stimulatedwith 100 nM
insulin. Stimulation was for 30 min in the case of HeLa cells, while C2C12 cells were stimulated for 2 h, and okadaic acid (0.2 μM)was added to themedium during the last hour of insulin
treatment. 10 μg of proteins from cell lysates was analyzed byWBwith the indicated antibodies.WB towards the Akt target site phospho-Ser9 of GSK3βwas used to verify the occurrence
of insulin stimulation. E. HEK 293T cellswere transfectedwithHA-Akt1, HA-Akt2 or empty vector (e.v.) and treated,where indicated, for 2 hwith 0.2 μMokadaic acid. 10 μg of proteinswas
analyzed by WB with the indicated antibodies.
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phosphorylated Ser129 shows a reduction of the signal upon both
Akt1 and Akt2 siRNA treatments, compared to aspeciﬁc siRNA-treated
cells. We ﬁnally immunoprecipitated endogenous Akt2 with isoform
speciﬁc antibodies from C2C12 and U2OS cells, and we found that
in neither case the IP reacts with anti-phosphoSer129 antibody
(not shown).
The results so far described were surprising, since, as already men-
tioned, from the sequence analysis we expected that Akt2 should have
been phosphorylated by CK2 on the site homologous to Akt1 Ser129.
We reasoned that two residues could be theoretically phosphorylated
by CK2 in this region of Akt2 (Ser131 and Thr132, both displaying the
S/T-X-X-E consensus for CK2) and that a double phosphorylationcould impair the reactivity of the phospho-speciﬁc antibody, as already
observed in similar cases [40]. Thus, to assess Akt2 phosphorylation by
an antibody-independent protocol, we performed an in vitro radioac-
tive kinase assay where Akt2 immunoprecipitated from Akt2 overex-
pressing cells was incubated with recombinant CK2α and [γ-33P]ATP.
While parallel experiments run with Akt1 promoted its radiolabeling,
no radiolabeling of Akt2 could be observed (Fig. 3, ﬁrst three lanes).
Similar results were obtained when the holoenzyme α2β2 was
used instead of the free α catalytic subunit of CK2 (not shown).
We then hypothesized that our in vitro experiments could fail if a
previous stoichiometric phosphorylation of Akt2 had occurred
in vivo, preventing further incorporation of radioactive phosphate.
To check this possibility, we performed experiments of Akt1 and 2
Fig. 2. Lack of reactivity of endogenous Akt2 with anti-phospho-Ser129. A. Total lysates of
cells from different lines were analyzed byWB with the indicated antibodies. 20 μg were
loaded for anti-Akt1 andAkt2WB and 50 μg for anti Sp129WB. B. C2C12 cellswere treated
with Akt1-speciﬁc, or Akt2-speciﬁc siRNA, or aspeciﬁc siRNA (ctrl), as indicated. 20 μg of
proteins from cell lysated was analyzed by WB with the indicated antibodies. Anti-α-
tubulin was used as loading control.
Fig. 3. IP Akt2 is not phosphorylated by CK2a in vitro. Anti-HA immunoprecipitates from
lysates of HEK 293T cells transfected with HA-Akt1, HA-Akt2 or empty vector, were incu-
bated with recombinant CK2α and a radioactive phosphorylation mixture. Then IP was
separated by SDS-PAGE, blotted, and analyzed for radioactivity by digital autoradiography
(Cyclone Plus); WB with anti-Akt is also shown as control of the IP amount.
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(Fig. 3, last three lanes), or with pre-treatment of the lysates with the
aspeciﬁc λ-phosphatase to remove phosphate possibly present at the
CK2 sites (not shown). These procedures, while triggering the phos-
phorylation of new sites in co-precipitating bands (Fig. 3, compare last
threewith ﬁrst three lanes), did not evoke any labeling of Akt2, suggest-
ing that this Akt isoform is totally refractory to any CK2-dependent
phosphorylation. We also performed a mass spectrometry analysis of
Akt2 overexpressed and immunoprecipitated from HEK 293T cells. Al-
though small amounts of phosphate were found at Ser128 and also at
Ser126 (sites not displaying the consensus for CK2, see Fig. 1A), no
phosphorylation was observed between Ser131 and Thr133 (Fig. 4).
To note that our data are in good agreement with information available
in the PhosphoSitePlus database (www.phosphosite.org), where the
phosphorylation of Akt Ser129 is well documented in Akt1, while the
homologous site in Akt2 has never been reported as phospho-site.
We then exploited recombinant Akt for an in vitro kinase assay
with recombinant CK2; surprisingly we found that CK2 does phosphor-
ylate Akt2, with an efﬁciency quite similar to that displayed with
Akt1 (Fig. 5A). Moreover, we also observed that pre-heating of
immunoprecipitated Akt2, before the in vitro kinase assay, evokes the
phosphorylation by CK2 (while inducing very little effects on Akt1
phosphorylation by CK2) (Fig. 5B). The site phosphorylated on Akt2
under these conditions was Ser131, since the mutation of Ser131 to
Ala almost abolishes the phosphorylation (Fig. 5B). However, probably
due to the low amount of phosphate incorporated by CK2 in this kind
of experiments and to the lower sensitivity of WB compared to radioac-
tive techniques, we were unable to appreciate any signal of anti-
phosphoSer129 promoted by the in vitro reaction, either in the case of
Akt1 or Akt2 (not shown).
We then tried to understand the reason for this sharp difference be-
tween Akt1 and Akt2. The ﬁnding that Akt2 IP is phosphorylated by CK2
only after a pre-heating treatment can be explained by assuming either
an Akt2 conformation which, under native conditions, masks the linker
region where the CK2 target site is located, or a hindrance due to other
proteins in complex with Akt2, which are removed upon thermal dena-
turation. In both cases, the event appears to be speciﬁc for Akt2. It has
been reported [41,42] that an intramolecular disulﬁde bond may occur
between Cys124, speciﬁcally present in the Akt2 linker region (but not
in Akt1), and a Cys, presumably Cys297/Cys311, of the catalytic domain.
This suggested to us the experiments shown in Fig. 6, where DTT was
added to the cells (Fig. 6A) or during the phosphorylation of IP Akt
(Fig. 6B), to prevent or revert the disulﬁde bond formation. However,
we did not observe any effect in the degree of CK2-dependent Akt2
phosphorylation. We also generated an Akt2 Cys124Ala mutant and
expressed it in cells, but we did not ﬁnd any Ser131 phosphorylation
(Fig. 6C). These data support the view that Akt2 phosphorylation by
CK2 is not prevented by a S\S bond involving Cys124.
Since Akt1 and Akt2 have been reported to display a different pat-
tern of subcellular distribution [7,43], in vivo absence of Akt2 Ser131
phosphorylation could be explained by the failure of CK2/Akt2 to co-
localize. To check this possibility, we performed confocal microscopy
immunoﬂuorescence experiments in cells overexpressing Akt1 and
Akt2; the results, shown in Fig. 7, demonstrated that CK2 co-localizes
with both the Akt isoforms, excluding also this possible explanation
for their different susceptibilities to CK2 phosphorylation.
At present, we do not have an obvious explanation for the lack of
Akt2 Ser131 phosphorylation, although the association with still un-
known proteins preventing CK2 access to the site, could be a possible
one, at least in cells. A differential pattern of co-precipitating proteins
was indeed visible upon Coomassie Blue staining of Akt1 and Akt2 im-
munoprecipitates from HEK 293T cells (not shown).
We thenmoved to analyze if the presence or the absence of the CK2-
phosphorylated site may be relevant for the functional differences
reported for Akt1 and Akt2. To this purpose, we exploited the mutant
of Akt1 not phosphorylatable by CK2, Ser129Ala, and a putative
Fig. 4.MS/MS spectrum of the TiO2 captured phosphopeptide CGSPSDSSTTEEMEVAVSK. The sequence starts at Akt2 Cys124 and the methionine in the peptide is oxidized. The mass
indicates that the sequence is monophosphorylated. The b and y ion masses are shown in bold if present as either the single or doubly charged ions intact or with phosphate loss marked
as−p or if present as losses of−64 (methionine side chain loss) or−17 (ammonia). Manual interpretation shows that S128 is phosphorylated but also that co-eluting is another peptide
with the phosphate on S126. There is no evidence for phosphorylation on any of the other serines or threonines. No other phosphopeptides were found (singly or multiply
phosphorylated).
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er, that the phosphomimetic mutant of Akt1, Ser129Asp, was found un-
able to produce the effects of phospho-Ser129 [32]).Whenwe analyzed
the Akt-dependent phosphorylation pattern in transfected cells by
western blot with an anti-Akt phospho-motif antibody, we did not ob-
servemajor differences between the different Akt isoforms andmutants
(Fig. 8A), and the same occurred when we performed WB with
phospho-speciﬁc antibody for individual Akt substrates, such as AS160
[44] or PRAS40 [45] (not shown). Ser129 phosphorylation has been
demonstrated to be important for the β-catenin-dependent regulation
of survivin expression [46]; however, in our hands no difference is ob-
servable on survivin levels between cells overexpressing Akt1, Akt2
and mutants (not shown).
We then tried to assess the phosphorylation of palladin, an actin-
associated protein reported to be a target of Akt1 but not of Akt2 [21],
and whose phosphorylation speciﬁcally requires the Akt1 linker seg-
ment, where Ser129 is located. In this case we performed immunopre-
cipitation of the endogenous palladin from Akt transfected cells,
followed by WB with Akt phospho-motif antibody, as in [21]. As
shown in Fig. 8B, we found that indeed the palladin phosphorylation
level in cells transfected with Akt1 is signiﬁcantly higher than in Akt2-
transfected cells; particularly relevant for this work, we also found
that the Akt1 mutant not phosphorylatable at Ser129 produces a low
phosphorylation level, very similar to that observed with Akt2. More-
over, since itwas also found thatAkt1 but not Akt2 associates to palladin
[21], we performed co-immunoprecipitation experiments and found
that the amount of Akt1 Ser129Ala mutant associated to palladin is
much lower than that of w.t. Akt1 and instead similar to the Akt2
amount (Fig. 8B). The Ser131Asp Akt2 mutant also failed to restore
palladin phosphorylation and interaction to Akt2, whose levels, in
cells transfected with this mutant, are even lower than in the case of
w.t. Akt2. As pointed above, this result was not unexpected since the
Ser129Asp mutant is unable to mimic the effects of Ser129 phosphory-
lation [32] (see also Discussion).In conclusion, we think that our ﬁnd-
ings with the Akt1 Ser129Ala mutant strongly support a role of theCK2-dependent phosphorylation in determining the isoform speciﬁcity
of palladin targeting by Akt.
4. Discussion
Despite the high sequence identity of Akt1 and Akt2, the occurrence
of distinct functions for the two isoforms has been known for several
years: the ﬁrst suggestion for Akt isoform-speciﬁc roles dates back to
2001 [47], when it was reported that Akt2 plays a speciﬁc role in myo-
blast differentiation.
The problem of how two closely related kinases may perform dis-
tinct actions has been frequently discussed, usually invoking the phos-
phorylation of speciﬁc substrates as the most likely explanation.
Indeed, among the over 100 known substrates of Akt, several proteins
have been identiﬁed as speciﬁcally or preferentially targeted by one iso-
form, such as p21 [48], Skp2 [49] and palladin [21] phosphorylated by
Akt1, and HDM2 [50], Ankrd2/ARPP [51] and p27 [52] preferred by
Akt2. Many others exist (see [4,43] for reviews), and they can diverge
in different cell types and tissues.
However, once speciﬁc substrates have been found, the question
moves up, asking for the reason of such distinct substrate selectivity
and for possible differential recognitionmechanisms, which are still un-
known. Here we show that a substantial difference between Akt1 and
Akt2 occurs at the linker region, where only Akt1, but not Akt2, is phos-
phorylated in cells by CK2. The linker region is a short segment (about
40 amino acids) spanning between the PH and the catalytic domains.
Its structure and tridimensional connections to the other parts of the
molecule have never been clearly described, but it is expected to play
a special role in the important regulation mechanism by which the PH
domain can be “in” or “out”with respect to the catalytic domain, confer-
ring close (inactive) or open (active) conformation states, respectively
[53,54].
The importance of the linker region in determining some of the Akt
isoform-speciﬁc functions has been documented: Chin and Toker ele-
gantly showed that, while the expression of palladin is regulated by
Fig. 5. CK2 phosphorylates recombinant and denaturated Akt2. A. 0.1 and 0.5 μg of recombinant His-tagged Akt1 and Akt2were incubated with a radioactive phosphorylation mixture, in
the presence of recombinant CK2αwhere indicated (+). Samples were run on SDS-PAGE, blotted, and analyzed for radioactivity and by anti-HisWB. The digital autoradiography andWB
of a representative experiment are shown, while the graph reports the normalized values of Akt1 and Akt2 phosphorylation by CK2 (+SD) of three independent experiments. B. Akt1 or
Akt2 (w.t. or Ser131Alamutant)was IP from lysates of overexpressing cells, then subjected to phosphorylation byCK2 directly, or after a 20min pre-incubation at 60 °C, as indicated. Other
conditions as in Fig. 3. Upper panel shows an experimentwith Akt2 in the presence or in the absence of CK2α, while lower panels showa comparison between Akt1 and Akt2 and between
Akt2 w.t. and Ser131Ala mutant.
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a chimera presenting the Akt2 PH followed by Akt1 domains, linker in-
cluded, phosphorylates palladin, while a chimera containing the PH and
the linker of Akt2 followed by Akt1 domains does not. Also Zhou and co-
workers [56], by using a domain swap strategy, concluded that the link-
er region “distinguishes Akt1 from Akt2 while the other domains are
largely interchangeable”, and Kim and coauthors demonstrated that
“the linker region of Akt1 is responsible for the induction of migration
in DKO cells” [57]. Our data, showing a different phosphorylation state
of the Akt1 and Akt2 linker region, suggest a possible regulatorymechanism which can be exploited for ﬁne tuning of Akt activity and
substrate selectivity. Bymeans ofWBwith phospho-speciﬁc antibodies,
we tested the phosphorylation level of Akt substrates in Akt overex-
pressing cells, looking for something speciﬁcally affected by the muta-
tion of Akt1 Ser129 to Ala. With an Akt phospho-motif antibody, we
did not observe major differences, despite an activity slightly lower for
Akt2 and Akt1 Ser129Ala mutant compared to w.t. Akt1. This was al-
ready reported for the Akt1 mutant [31], and is also in accordance
with the previous ﬁnding [58] that Akt2 has a lower intrinsic catalytic
activity; our results suggest that its lack of phosphorylation by CK2
Fig. 6.A disulﬁde bond is not involved in preventing Akt2 Ser131 phosphorylation. A. HEK
293T cells were transfected as indicated and treated for 5 h with 5 mM DTT. 10 μg of cell
lysate proteins was analyzed by WB with the indicated antibodies. Anti-actin was used
as loading control. B. Akt1 or Akt2was IP from overexpressing cells, then IPwas incubated
with recombinant CK2α and radioactive mixture as in Fig. 2, but in the presence of 2 mM
DTT, where indicated (+). Samples were solved by SDS-PAGE and blotting, and analyzed
at Cyclone for radioactivity incorporated in the IP bands and by anti-Akt WB for the
amount of Akt IP. C. HEK 293T cells were transfected with the indicated plasmids. 10 μg
of cell lysate proteins was analyzed byWB for phospho-Ser129 or for the Akt-tag HA.
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that palladin phosphorylation and association are higher with Akt1
w.t. thanwith Akt1 Ser129Ala (Fig. 8), indicating that Ser129 phosphor-
ylation is involved in the recognition of this substrate, and providing an
explanation of why Akt2, whose linker region is not phosphorylated byFig. 7. Co-localization of CK2 with HA-tagged Akt1 and Akt2. HeLa cells were transfected as ind
immunostaining with anti-CK2α (red) and anti-HA (green); nuclei are stained in blue with HoCK2 in cells, has also a low efﬁciency in targeting palladin.We also tried
to force Akt2 phosphorylation of palladin by exploiting a Ser131Asp
mutant designed tomimic phosphorylation; theﬁnding that themutant
did not recapitulate the effects of phosphorylation was also found for
the Akt1 mutant Ser129Asp [32], and suggests that structural elements
different from (or in addition to) just the negative charges are involved
in the functions of this phospho-site, as sometimes occurs and as al-
ready demonstrated also for the crucial Akt phospho-site Thr308 [59].
Currently, we donot have a full explanation for the differential phos-
phorylation by CK2 of the Akt isoforms, since both Akt1 Ser129 and the
homologous Ser131 in Akt2 display the consensus for CK2 (Fig. 1A). Ac-
cordingly, recombinant Akt2 is phosphorylated by CK2 in in vitro assay
(Fig. 5A), indicating that events occurring in vivo prevent Akt2 phos-
phorylation by CK2.
It has been reported that Akt1 and Akt2 have different subcellular
localization, with possible variability according to the cell type and con-
ditions [7,43]. Interestingly, Santi and Lee found Akt2 mainly at mito-
chondria [7]; in principle, this could explain a lower level of Akt2
phosphorylation by CK2 in cells, being CK2mostly present in the cytosol
and the nucleus, and less abundant in mitochondria. However, in our
experimental conditionswe found that both Akt1 andAkt2weremainly
in the cytosol and the nucleus, showing similar co-localizationwith CK2
(Fig. 7), suggesting that the reason for the failure of Akt2 Ser131 phos-
phorylation is to be found elsewhere. We also excluded the possibility
that a disulﬁde bond between the linker region and the catalytic do-
main, speciﬁcally present in Akt2 [41], could be responsible for the
lack of accessibility to Ser131 by CK2 (Fig. 6). We have therefore to as-
sume that other structural features are intrinsically present in Akt2 con-
formation that prevent CK2 access to the linker region, and can be
removed by thermal denaturation (Fig. 5B). Theoretically partner pro-
teins might be speciﬁcally associated to Akt2 in vivo and interfere
with its phosphorylation by CK2. On this regard, many partner proteins
have been reported to stably associate with Akt, and in some cases iso-
form speciﬁcity has been found. For example, p21 is a substrate of Akt1,
but associates selectively to Akt2 [48]. Also the CTMP protein which
binds to the C-terminal region of Akt [60] has been suggested to poten-
tially differ in its interaction with Akt isoforms [43]; moreover CKIP-1
[61], even if reported as associated to all Akt isoforms, seems to have a
higher afﬁnity for Akt2. Our experimental conditions allowed several
proteins (not yet identiﬁed) to differently co-precipitate with Akt1
and Akt2 (not shown); in principle, each of them could be responsible
of favoring or preventing CK2-dependent phosphorylation of Akt1 andicated. Representative images are shown of confocal microscopy experiments obtained by
echst. In the “merge” panels, yellow indicates co-localization of CK2 and Akt.
Fig. 8. Differential phosphorylation and association of palladin to Akt variants. HeLa cells
were transfected with HA-tagged Akt variants or empty vector (e.v.) as indicated, and
treated as described under Materials and methods. A. 5 μg of proteins from total lysates
was analyzed with the indicated antibodies. Actin was used as loading control. In the
WBwithAkt P-motif, the signal evoked byprevious incubationwith anti-HA is highlighted
by an arrow. B. Palladin was immunoprecipitated from total lysates, as described under
Materials and methods. Pellets were analyzed for Akt-dependent phosphorylation
(WB Akt P-motif), for the amount of immunoprecipitated palladin (WB palladin) and
for the presence of co-precipitated Akt (WB HA). Where relevant, the migration of the
major palladin bands in HeLa (140 and 95/100 kDa) is indicated. The bar graph corre-
sponds to the quantization of the 95/100 kDa palladin band phosphorylation as deter-
mined by Akt P-motif WB analysis with the Kodak 1D Image software (means ± SD of
three independent experiments).
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identity of the associated proteins and their involvement in preventing
Ser131 phosphorylation.Ourmass spectrometry data on Akt2 puriﬁed from cells revealed the
presence of phosphate on residues in the vicinity of Ser131, namely
Ser128 (homologous to Ser126 of Akt1) and traces on Ser126 (Ser124
in Akt1) (Fig. 4). Their surrounding sequences do not fulﬁll the consen-
sus for CK2, especially in the case of Ser126, being a Pro in+1 a negative
determinant for CK2 phosphorylation [37]. These sites had already been
reported as phosphorylated in Akt1 [62,63] and, for Ser126, also in Akt2
[64], without the identiﬁcation of the kinases involved.We reasoned on
the possibility that the phosphorylation of these sites dictates structural
conditions not compatible for further phosphorylation of Ser131 in Akt2
(while sequence diversity would allow Ser129 phosphorylation in
Akt1). However, when we performed the experiments of Akt2 phos-
phorylation by CK2 after previous treatmentwith an aspeciﬁc phospha-
tase (not shown) or omitting phosphatase inhibitors during cell lysis
(Fig. 3) (thus possibly removing the phosphate present on these resi-
dues), we did not observe any Ser131 phosphorylation. This makes it
unlikely that previous phosphorylation sites are relevant in preventing
CK2-dependent phosphorylation of Akt2. Incidentally, it is worth to
note that our ﬁndings are in agreement with previous papers reporting
Akt phosphorylated residues, where, among other sites, phosphate was
found on Akt1 Ser129 [63], but not on Akt2 Ser131 [64], and with data
reported on PhosphoSitePlus (www.phosphosite.org).
5. Conclusions
Ourwork, by showing that only Akt1 is phosphorylated in the linker
region by protein kinase CK2, discloses an important feature which dis-
criminates between Akt1 and Akt2 and is crucial for the recognition by
Akt1 of the isoform-speciﬁc substrate palladin. This suggests that the
linker phosphorylation plays a role in the ﬁne-tuning of processes con-
trolled by a speciﬁc isoform, thus providing a molecular explanation of
the Akt1/Akt2 divergent functions.
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